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Introduction
Although hypertension is a major risk factor for stroke, myocardial 
infarction, and kidney failure (1), surprisingly little is known about 
the genetic mechanisms that contribute to its development. GWAS 
have begun to identify common genetic variants that contribute to 
variations in blood pressure (BP) (see refs. 2, 3 for reviews). While 
some of these loci have been fairly well characterized, others are 
found within genes that have no known connection to the control 
of BP. One such locus was identified on chromosome 11 within the 
GTPase-activating protein (GAP) ARHGAP42 (4–6). The minor 
allele at this locus was associated with a decrease in BP of about 
0.5 mmHg per allele and had a minor allele frequency (MAF) of 
0.27 in the European population in which it was identified (5).
ARHGAP42, also known as GRAF3, is a member of the GRAF 
(GAP for Rho associated with focal adhesion kinase) family of 
Rho-specific GAPs previously characterized by our group (7–10). 
Based on our demonstration that ARHGAP42 was highly and 
selectively expressed in smooth muscle in mouse and human tis-
sues (11) and the fact that Rho GTPase RhoA signaling controls 
smooth muscle cell (SMC) contractility (12), we hypothesized 
that ARHGAP42’s association with BP was mediated by its abil-
ity to modulate vascular resistance. Indeed, Arhgap42-deficient 
mice exhibited significant hypertension and increased pressor 
responses to ANGII and endothelin 1, and these effects were 
prevented by treatment with the Rho kinase (ROCK) inhibi-
tor Y-27632 (11). Further supporting this idea, we showed that 
large and small arteries from Arhgap42-deficient mice exhibited 
increased contractility in vitro and in vivo, while kidney structure 
and function were unchanged.
According to the HaploReg v4 database from the Broad 
Institute, the BP-associated allele in the European population 
is currently defined by 4 SNPs (rs604723, rs633185, rs607562, 
and rs667575) in high linkage disequilibrium (LD) (r2 > 0.8). 
Importantly, all of these SNPs are present within the noncoding 
80-kb first intron of ARHGAP42. Thus, we hypothesized that 
minor allele variations within the BP-associated locus increase 
ARHGAP42 expression by enhancing the transcriptional activi-
We recently demonstrated that selective expression of the Rho GTPase-activating protein ARHGAP42 in smooth muscle 
cells (SMCs) controls blood pressure by inhibiting RhoA-dependent contractility, providing a mechanism for the blood 
pressure–associated locus within the ARHGAP42 gene. The goals of the current study were to identify polymorphisms that 
affect ARHGAP42 expression and to better assess ARHGAP42’s role in the development of hypertension. Using DNase I 
hypersensitivity methods and ENCODE data, we have identified a regulatory element encompassing the ARHGAP42 SNP 
rs604723 that exhibits strong SMC-selective, allele-specific activity. Importantly, CRISPR/Cas9–mediated deletion of this 
element in cultured human SMCs markedly reduced endogenous ARHGAP42 expression. DNA binding and transcription 
assays demonstrated that the minor T allele variation at rs604723 increased the activity of this fragment by promoting 
serum response transcription factor binding to a cryptic cis-element. ARHGAP42 expression was increased by cell stretch 
and sphingosine 1-phosphate in a RhoA-dependent manner, and deletion of ARHGAP42 enhanced the progression of 
hypertension in mice treated with DOCA-salt. Our analysis of a well-characterized cohort of untreated borderline hypertensive 
patients suggested that ARHGAP42 genotype has important implications in regard to hypertension risk. Taken together, our 
data add insight into the genetic mechanisms that control blood pressure and provide a potential target for individualized 
antihypertensive therapies.
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than those containing the major allele, and control experiments 
with and without DNase and with and without reverse tran-
scriptase confirmed that these results were not influenced by 
contaminating genomic DNA (Supplemental Figure 1; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI88899DS1). In strong support of these findings, 
the NIH-sponsored Genotype-Tissue Expression (GTEx) Con-
sortium identified an expression quantitative trait locus (eQTL) 
at rs604723 by correlating ARHGAP42 mRNA levels in human 
tibial artery samples with ARHGAP42 genotype (13). As shown 
in Figure 1B, our more recent analysis of GTEx data revealed 
that ARHGAP42 mRNA levels in aorta and coronary artery sam-
ples were approximately 3-fold higher in samples taken from 
individuals homozygous for the minor allele at rs604723 than 
from individuals homozygous for the major allele. Aside from 
a relatively small difference in ARHGAP42 expression in sub-
cutaneous adipose (a highly vascularized tissue), ARHGAP42 
eQTLs were not detected in other organs, strongly supporting 
the idea that the BP effects of this locus are mediated by changes 
in ARHGAP42 expression in SMCs.
ty of a yet-to-be-identified regulatory element. The goals of the 
present study were to identify the transcription mechanisms 
that drive ARHGAP42 expression in SMCs, to test whether 
variations within the ARHGAP42 BP-associated locus affect 
ARHGAP42 transcription, and to further characterize the role 
of ARHGAP42 expression in the regulation of BP and the devel-
opment of human hypertension.
Results
Allele-specific differences of ARHGAP42 expression in SMCs. To 
begin to test our hypothesis that BP-associated variations in 
the ARHGAP42 gene have allele-specific effects on ARHGAP42 
expression in SMCs, we developed PCR primers that can distin-
guish between the major C and minor T alleles at the rs604723 
SNP and used quantitative PCR to measure ARHGAP42 mRNA 
levels in human aortic SMC (HuAoSMC) cultures that are het-
erozygous at the ARHGAP42 BP-associated locus. One caveat to 
this approach is that it can only measure unprocessed transcripts 
that contain the first intron. As shown in Figure 1A, ARHGAP42 
transcripts containing the minor allele were significantly higher 
Figure 1. ARHGAP42 expression in SMCs is regulated by allele-specific mechanisms and controls BP. (A) Total RNA isolated from HuAoSMCs hetero-
zygous at the rs604723 SNP (C/T) was subjected to first-strand cDNA synthesis using reverse transcriptase. Reaction products were then subjected to a 
TaqMan-based PCR assay using allele-specific primers to the ARHGAP42 rs604723 variation. Data represent mean ± SEM of n = 4 experiments; *P < 0.01 
vs. the major C allele (Student’s t test). (B) ARHGAP42 mRNA levels were measured by the Genotype-Tissue Expression (GTEx) Consortium. The minor T 
ARHGAP42 allele at the rs604723 polymorphism was significantly associated with increased ARHGAP42 expression in aortic and coronary artery samples. 
(C) Schematic of the Arhgap42 gene-trap and SM-MHCCreERT2 mice used for SMC-specific ARHGAP42 rescue experiments. (D) WT and Arhgap42gt/gt SM-
MHCCreERT2 mice were injected i.p. with vehicle (corn oil) or tamoxifen (100 mg/kg) for 5 consecutive days as indicated. Two weeks after the last injection, BP 
was measured by tail cuff method, and Arhgap42 mRNA levels in the aorta were measured by semiquantitative RT-PCR analysis using primers to exons 1 
and 4. Data are expressed as mean ± SEM; n = 6 for WT and Arhgap42gt/gt SM-MHCCreERT2 mice with vehicle treatment, n = 5 for Arhgap42gt/gt SM-MHCCreERT2 
mice with tamoxifen treatment. *P < 0.05 vs. WT; **P < 0.05 vs. corn oil–treated (ANOVA). Note that tamoxifen treatment restored Arhgap42 expression 
and reduced BP to WT levels (representative of 3 separate experiments).
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exhibited hypertension trended lower in subjects who had 
copies of the minor allele (69%, 64%, and 60% for the C/C, 
C/T, and T/T genotypes, respectively). Finally, the MAF of 
the protective T allele in this cohort was dramatically lower 
in African Americans than in subjects of mixed European 
descent (6.5% vs. 26.6%; P < 0.001), and sequencing of 
over 1,000 individuals from this and additional University 
of North Carolina cardiovascular cohorts (17–20) confirmed 
this result (Supplemental Table 2).
Identification of regulatory elements within the ARHGAP42 
gene. It is clear that gene regulatory regions exhibit distinct 
chromatin signatures, and we and others have shown that 
SMC-specific gene expression is regulated by alterations in 
chromatin structure (21–24). Thus, to prioritize our search 
for regulatory regions that drive ARHGAP42 expression, 
we performed DNase hypersensitivity measurements in 
HuAoSMCs to identify regions of open chromatin. As shown 
in the ARHGAP42 gene schematic in Figure 2A, we identi-
fied 2 approximately 600-bp DNase hypersensitivity sites 
(DHS1 and DHS2) within the first intron and a larger DHS 
that covered about 2 kb of the transcription start site (TSS). 
Additional analyses of Encyclopedia of DNA Elements 
(ENCODE) data sets revealed that all 3 regions were marked by 
histone modifications known to be associated with transcription-
ally active regions (i.e., H3K4 methylation and H3K27 acetylation) 
and contained stretches of highly conserved sequence. Of par-
ticular interest, the rs604723 SNP was in the middle of a highly 
conserved 100-bp region at the center of the DHS2. All 3 regions 
were PCR-amplified from human genomic DNA and cloned into 
the pGL3 luciferase vector. It is important to note that the DHS1 
region was extended to include the nearby SNP rs633185, so 
that the functional effects of this variation could be tested. Also, 
because the other 2 SNPs within the BP-associated LD block 
(rs607562 and rs667575) were not near open chromatin regions 
or conserved DNA sequences, we did not further examine their 
contributions to ARHGAP42 expression.
As shown in Figure 2B, the DHS2 exhibited very strong tran-
scriptional activity (38-fold over the promoterless pGL3 vector) 
that was significantly higher in SMCs than in endothelial cells 
(ECs), suggesting that this element is an important driver of 
SMC-selective ARHGAP42 expression. The TSS exhibited moder-
ate activity in SMCs and in ECs, consistent with the idea that it 
functions as more of a basal promoter. We next used site-direct-
ed mutagenesis to generate allelic series for the rs633185 and 
rs604723 SNPs within the context of the DHS1 and DHS2 regula-
tory elements, respectively. As shown in Figure 2C, the DHS2 con-
taining the minor T allele exhibited significantly higher activity 
than the DHS2 containing the major C allele, while the variation at 
rs633185 had no effect on the relatively low SMC-selective activity 
of the DHS1 region. Interestingly, the rs604723 variation did not 
affect DHS2 activity in ECs.
To test whether the DHS2 element was required for expres-
sion of the endogenous ARHGAP42 gene, we used CRISPR/Cas9–
mediated gene editing to delete the 100-bp conserved element 
within the DHS2 in human bronchial SMC (HuBrSMC) cultures 
(Figure 2D). Although we observed somewhat variable deletion 
efficacy (from 45% to 95% in 5 separate experiments), our deletion 
ARHGAP42 expression in SMCs controls BP. To provide addi-
tional direct evidence that expression of ARHGAP42 in SMCs is 
critical for BP regulation, we rescued its expression in our hyper-
tensive global Arhgap42-deficient gene-trap mice (Arhgap42gt/gt) by 
crossing them to an SM-MHCCreERT2 line that expresses a tamoxi-
fen-inducible Cre under the control of the smooth muscle myosin 
heavy chain promoter (14). As shown in Figure 1C, the inhibitory 
Arhgap42gt/gt gene-trap cassette is flanked by loxP sites, and treat-
ment of Arhgap42gt/gt SM-MHCCreERT2 mice with tamoxifen per-
manently restored ARHGAP42 expression in aortic SMCs, and 
completely reversed the hypertensive phenotype in this model by 
2 weeks after tamoxifen treatment (Figure 1D and Supplemental 
Figure 2). These data provide conclusive evidence that ARHGAP42 
levels in SMCs control BP homeostasis and that the hypertensive 
phenotype in Arhgap42gt/gt mice was reversible and most likely due 
to an increase in SMC contractility.
ARHGAP42 genotype and human hypertension. To better 
assess ARHGAP42’s role in the development of human hyper-
tension, we genotyped a group of 346 borderline hypertensive 
patients who were part of a clinical study comparing the effective-
ness of BP monitoring protocols at the University of North Caro-
lina (refs. 15, 16, and Supplemental Table 1). Importantly, BPs in 
this group were extremely well characterized by repeated office 
measurements, and none of these individuals were being treat-
ed with antihypertensive therapies. Several findings illustrated 
in Table 1 are worth noting. First, we observed an age-indepen-
dent decrease in BP in subjects homozygous for the minor allele 
compared with subjects homozygous for the major allele (76.9 
mmHg vs. 81.8 mmHg; P = 0.028). The relative magnitude of this 
decrease (5 mmHg vs. 1 mmHg measured in GWAS) suggested 
that ARHGAP42’s effects on BP may be greater than originally 
estimated. Second, the MAF (as defined by rs604723) trended 
lower in the group of patients who were categorized as hyper-
tensive as defined by American Heart Association guidelines 
(systolic BP > 140 mmHg), and the percentage of subjects that 
Table 1. Analysis of ARHGAP42 genotype and BP in human populations
rs604723 Genotype C/C C/T T/T
Systolic BP (mmHg) 130.3 130.2 126.3
Diastolic BP (mmHg) 81.8 81.1 76.9A
rs604723 Genotype C/C C/T T/T MAF
Mixed European descent 147 108 19 26.6%
African American 54 8 0 6.5%B
Other 5 8 1 35.7%B
rs604723 Genotype C/C C/T T/T MAF
HTN (%) 141 (69) 78 (64) 12 (60) 22.1%
Non-HTN (%) 64 (31) 44 (36) 8 (40) 26.1%
A group of 346 borderline hypertensive patients (see Supplemental Table 1 for more 
detailed characteristics of this group) were genotyped at the rs604723 variation 
using a TaqMan-based allelic discrimination assay. The resulting genotypes were 
then correlated with repeated office BP measurements or hypertension (HTN) 
status (i.e., greater or less than 140 mmHg) or grouped by race. AP < 0.05 vs. 
diastolic BP measured in patients homozygous for the major allele (C/C); BP < 0.001 
vs. MAF in patients of mixed European descent; χ2 test.
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complexes, 1 of which had a mobility similar to that of serum 
response factor (SRF), a transcription factor known to be critical 
for SMC-specific gene expression (see ref. 25 for a review). Inter-
estingly, the presence of the minor T allele at rs604723 results in a 
DHS2 sequence that conforms to a consensus SRF-binding CArG 
element at 8 out of 10 residues, while the presence of the major 
C allele within the A/T-rich region would be predicted to inhibit 
SRF binding to this sequence (Figure 3A). To test the involvement 
of SRF, we performed additional gel shift assays using recombi-
nant SRF protein. Our results clearly show that the minor T allele 
sequence interacted with SRF while the major C allele sequence 
protocol resulted in a significant decrease in ARHGAP42 mRNA 
expression (Figure 2E). These results strongly support our conclu-
sion that the DHS2 region regulates ARHGAP42 expression and 
that rs604723 is the functional SNP in this BP-associated LD block.
The minor allele sequence at rs604723 binds serum response 
factor. To begin to identify the mechanisms that mediate the tran-
scriptional activity of the DHS2 fragment and the effects of the 
minor T allele variation, we used gel shift assays to compare pro-
tein binding to 100-bp probes that encompassed the highly con-
served region at the center of the DHS2. As shown in Supplemental 
Figure 3, we observed 2 relatively weak T allele–specific binding 
Figure 2. An enhancer within the ARHGAP42 first intron displays strong SMC-specific and allele-specific activity and is required for endogenous  
ARHGAP42 expression. (A) Map of the chromatin determinations used to characterize potential regulatory elements near the ARHGAP42 BP-associated 
locus. The SNPs that define the BP-associated allele (r2 > 0.8) are shown at the top. (B) The indicated DNase-hypersensitive (DHS) regions were cloned 
into the pGL3 luciferase vector and transfected into primary human bronchial SMCs and mouse ECs. Luciferase activity in cell lysates was measured 2 days 
later and is expressed as fold over the promoterless pGL3 vector. Data represent mean ± SEM of n = 6 experiments; *P < 0.001 vs. in ECs (Student’s t test). 
(C) Site-directed mutagenesis was used to test the effects of the major/minor alleles on DHS1 and DHS2 enhancer activity. Data represent mean ± SEM of  
n = 6 experiments; *P < 0.01 vs. the major allele (Student’s t test). (D) Schematic of the 102-bp deletion (in red) generated by our CRISPR/Cas9–mediated 
gene editing protocol. (E) ARHGAP42 message was measured by semiquantitative RT-PCR in human bronchial SMC cultures transfected with expression 
plasmids encoding Cas9 and the guide RNAs shown in D (n = 5). The reduction in ARHGAP42 expression was normalized to the efficiency of DHS2 deletion, 
which ranged from 45% to 95%. Data represent mean ± SEM of n = 5 separate experiments; *P < 0.05 vs. cells transfected with empty guide RNA expres-
sion plasmid (Student’s t test).
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revealed that the DHS2 region containing the T allele sequence 
was in a more active chromatin conformation (Figure 3F).
SRF is required for ARHGAP42 expression and for the effects of 
the rs604723 variation. To test whether ARHGAP42, like most 
other SMC-specific markers, is regulated by SRF, we used several 
gain/loss-of-function approaches. As shown in Figure 4A, overex-
pression of the SRF cofactor myocardin in HuBrSMCs transacti-
vated the DHS2-luciferase fragment containing the minor T allele 
12-fold, but had significantly less of an effect on the DHS2 frag-
ment containing the major C allele. Moreover, knockdown of SRF 
in these cells by siRNA decreased the transcriptional activity of the 
DHS2 minor allele to a level that was similar to that of the major 
allele (Figure 4B). Importantly, SRF knockdown in our HuAoSMC 
did not (Figure 3B). Similar results were obtained when biotin-
labeled T and C allele oligonucleotide probes were conjugated to 
avidin-coated beads and used to precipitate SRF from SMC lysates 
(Figure 3C). We next used ChIP assays to test whether SRF bound 
to the DHS2 in the context of the endogenous ARHGAP42 gene. 
As shown in Figure 3D, we observed significant SRF binding in our 
HuAoSMCs that are heterozygous (C/T) at rs604723 but no bind-
ing when ChIP assays were performed in human coronary SMCs 
that are homozygous major (C/C) at this sequence. Moreover, 
the increased presence of T allele–containing DNA in SRF immu-
noprecipitates (Figure 3E) strongly suggested that SRF interacts 
more readily with this sequence in the context of the endogenous 
gene, and targeted allele-specific DNase hypersensitivity assays 
Figure 3. The minor T allele at rs604723 promotes SRF binding. (A) Schematic of sequence conservation at the center of the DHS2 region and of CArG 
homology at the rs604723 SNP. (B) Gel shift assays were performed by combining recombinant SRF (rSRF) with radiolabeled 100-bp oligonucleotide probes 
containing the major or minor alleles at rs633185 and rs604723. Representative image shown from n = 2. (C) Biotin-labeled 20-bp oligonucleotides containing 
the major C or minor T allele at rs604723 or a consensus CArG element were conjugated to streptavidin beads and incubated with HuAoSMC nuclear extracts. 
Washed immunoprecipitates were analyzed for the presence of SRF by Western blotting. Data are representative of 2 separate experiments. (D) ChIP assays 
were used to measure SRF binding to the DHS2 region in cultured HuAoSMCs and HuCoSMCs that are heterozygous (CT) and homozygous major (CC) at the 
rs604723 SNP, respectively. Data represent mean ± SEM of n = 4 experiments; *P < 0.05 vs. IgG in HuAoSMCs (Student’s t test). (E) SRF-ChIP immunoprecipi-
tates from HuAoSMCs were subjected to a TaqMan-based assay that discriminates between the major and minor alleles at the rs604723 SNP. Data represent 
mean ± SEM of n = 4 experiments; *P < 0.01 vs. major allele (Student’s t test). (F) Increasing amounts of DNase I (0–1 μg) were added to permeabilized nuclei 
isolated from HuAoSMCs. Following genomic DNA isolation, allele-specific primers were used to amplify a 300-bp region containing the rs604723 SNP. Data 
represent mean ± SEM of n = 3 experiments; *P < 0.05 (Student’s t test).
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line also decreased the level of endogenous ARHGAP42 message 
containing the minor allele as measured by our allele-specific 
reverse transcription PCR (RT-PCR) methods (Figure 4C).
ARHGAP42 expression is upregulated by RhoA signaling. We and 
others have shown that RhoA signaling enhances SMC-specific 
gene expression by promoting the nuclear localization of the myo-
cardin-related transcription factors (MRTFs) (26–28). In support of 
this mechanism, Arhgap42 expression in primary rat aortic SMCs 
was upregulated by sphingosine 1-phosphate, a strong activator of 
RhoA signaling in many cell types, including SMCs (29), and this 
effect was abolished by pretreatment with the ROCK inhibitor 
Y-27632 (Figure 5A). Physical forces such as cell stretch and tension 
are also well-known activators of RhoA signaling and are known to 
be increased in the vessel wall under hypertensive conditions (30). 
As shown in Figure 5B, Arhgap42 mRNA levels were significantly 
upregulated in SMC cultures subjected to cyclic stretch using the 
FX-4000T Flexcell system, and this effect was also ROCK-depen-
dent. Arhgap42 mRNA levels were also upregulated in isolated por-
tal vein segments subjected to static stretch (Figure 5C). The fact 
that LacZ expression was upregulated by stretch in portal veins iso-
lated from Arhgap42 LacZ gene-trap mice strongly indicated that 
this effect was mediated transcriptionally (Figure 5D).
Activation of ARHGAP42 expression attenuates the development 
of hypertension. Since RhoA/MRTF/SRF-dependent upregulation 
of ARHGAP42 would serve as a transcriptionally mediated nega-
tive-feedback loop for RhoA signaling in SMCs, we postulated that 
this mechanism prevents excessive SMC constriction by hyper-
tensive signals. In support of this idea, and in accordance with the 
results of our cell stretch experiments, arterial Arhgap42 mRNA 
levels were significantly increased in mice made hypertensive by 
l-NAME or deoxycorticosterone acetate (DOCA)–salt regimens 
(Figure 6, A and B). To test whether upregulation of Arhgap42 
expression under these conditions counteracted the development 
of hypertension, we subjected WT and Arhgap42-deficient mice 
(Arhgap42gt/gt SM-MHCCreERT2) to a DOCA-salt regimen and moni-
tored BP by telemetry. Although the initial DOCA-salt–mediated 
increase in BP was similar in both groups (Figure 6C), BP in Arh-
gap42gt/gt SM-MHCCreERT2 continued to increase over the next week 
at a rate of 1.5 mmHg/d compared with 0.9 mmHg/d in WT mice 
(P < 0.05). As previously observed, the BP pressure difference 
between these 2 groups was completely reversed by treatment of 
Arhgap42gt/gt SM-MHCCreERT2 with tamoxifen, which also restored 
Arhgap42 expression (Supplemental Figure 4).
Discussion
We have previously shown that the Rho-specific GTPase-activating 
protein ARHGAP42 is highly and selectively expressed in SMCs 
and that global gene-trap–mediated reduction in ARHGAP42 lev-
els resulted in hypertension (11). By characterizing the transcrip-
tion mechanisms that control human ARHGAP42 expression, we 
have now identified a novel mechanism for the BP-associated locus 
within the ARHGAP42 first intron. Our data strongly indicate that 
rs604723 is the causative SNP at this locus and that the minor T 
allele variation increases ARHGAP42 expression by promoting SRF 
binding to an SMC-selective intronic regulatory element. Our dem-
onstration that the minor ARHGAP42 allele is more highly expressed 
in HuAoSMCs, when coupled with similar data from human artery 
samples, strongly supports our hypothesis that this variation reduces 
BP by inhibiting RhoA-dependent constriction of resistance vessels.
To our knowledge, this is the first demonstration of a genetic 
variant that alters SRF binding and that directly connects SRF func-
tion to a GWAS locus. Although we have not yet identified the pre-
cise mechanisms that control ARHGAP42 transcription, our data 
are in excellent agreement with the known role of SRF in the regu-
lation of SMC-specific gene expression (25). DHS2 transcriptional 
activity was responsive to myocardin overexpression, and knock-
down of SRF clearly decreased the activity of the DHS2 regulatory 
element and of endogenous ARHGAP42 mRNA containing the 
minor T allele. Because most SMC marker genes are regulated by 
multiple SRF-binding CArG elements (31–33), it will be important 
to determine whether additional CArGs are critical for endogenous 
ARHGAP42 expression. Interestingly, we saw little effect of SRF 
Figure 4. The allele-specific activity of the DHS2 enhancer 
is SRF-dependent. (A) Major and minor DHS2 luciferase con-
structs were transfected into HuBrSMCs along with myocardin 
or empty expression vector. Data represent mean ± SEM of 
n = 5 experiments; *P < 0.05 vs. major allele plus myocardin 
(Student’s t test). (B) DHS2-luciferase activity was measured 
in HuBrSMCs treated with control (NTC) or SRF siRNA. Data 
represent mean ± SEM of n = 6 experiments; *P < 0.01 vs. 
the minor allele (Student’s t test). (C) Allele-specific GRAF3 
mRNA levels were measured by semiquantitative RT-PCR in 
control and SRF knockdown HuAoSMCs. Data represent mean 
± SEM of n = 3 experiments; *P < 0.05 vs. the major C allele in 
control cells; **P < 0.05 vs. minor T allele in control cells (Stu-
dent’s t test). (D) Confirmation of SRF knockdown in SMCs 
treated with control or SRF siRNAs. Data are representative of 
3 separate experiments.
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knockdown on ARHGAP42 mRNA containing the major C allele. 
Although this may be explained by residual SRF expression in SRF 
knockdown cells, it may suggest that SRF is not absolutely required 
for expression of the major ARHGAP42 allele or that enhanced 
ARHGAP42 expression of the minor allele is more sensitive to SRF 
levels. The latter possibility would be consistent with the low bind-
ing affinity of this degenerate CArG element. The DHS2 fragment 
containing the major allele exhibits relatively high transcriptional 
activity suggesting that sequences outside of the SRF binding 
region are important, and we are currently attempting to identify 
the transcriptional mechanisms involved. It is also interesting to 
note that the DHS2 element had significant transcriptional activ-
ity on its own and when cloned upstream of a heterologous mini-
mal promoter (data not shown), suggesting that its contributions to 
ARHGAP42 transcription are complex and that it does not function 
as an enhancer in the traditional sense.
We cannot rule out the possibility that other SNPs in the 
rs604723 LD block play a role in the control of ARHGAP42 expres-
Figure 5. ARHGAP42 expression is activated by RhoA signaling and cell stretch. (A) Primary rat aortic SMCs were treated with 10 μM sphingosine 1-phos-
phate (S1P) with or without the ROCK inhibitor Y-27632. Arhgap42 expression was measured after 72 hours by semiquantitative PCR. Data represent mean 
± SEM of 4 experiments; *P < 0.001 vs. control; **P < 0.001 vs. S1P-treated (ANOVA). n = 4. (B) Using the FX-4000T Flexcell system, primary rat aortic SMCs 
were subjected to 0 (Ctrl) or 20% equibiaxial elongation at 1 Hz (cyclic strain). Arhgap42 message was measured at 18 hours by quantitative PCR. Data 
represent mean ± SEM; n = 3 from 2 independent experiments; *P < 0.001 vs. no cyclic strain; **P < 0.05 vs. minus Y-27632 (ANOVA). (C) Rat portal veins 
placed in ex vivo culture were subjected to 0 or 600 mg of static stretching force. At 72 hours Arhgap42 message was measured by semiquantitative RT-PCR. 
Graph shows ImageJ-based quantification of 3 independent experiments. *P < 0.05 (Student’s t test). (D) Portal veins isolated from Arhgap42+/gt mice were 
cultured ex vivo and subjected to 0 or 300 mg of static stretching force for 5 days. After LacZ staining, tissues were processed for standard microscopy 
including H&E staining. Scale bar: 200 μm. Data are representative of 3 independent experiments.
Figure 6. Arhgap42 expression limits the development of hypertension. (A) WT mice were treated with l-NAME (450 mg/l in drinking water). After 14 
days, BP was measured by tail cuff method, and Arhgap42 message in isolated mesenteric arteries was measured by quantitative PCR. Data represent 
mean ± SEM; n = 4 per group; *P < 0.05 vs. untreated (Student’s t test). (B) WT mice were implanted with a 50-mg slow-release DOCA pellet and then fed 
0.9% NaCl in drinking water. After 3 weeks, BP was measured by tail cuff method, and Arhgap42 message in aorta was measured by quantitative PCR.  
*P < 0.05 vs. untreated; n = 6 per group (Student’s t test). (C) Following radiotelemeter implantation and equilibration, 3 WT and 5 Arhgap42gt/gt SM-
MHCCreERT2 mice were implanted with a 50-mg slow-release DOCA pellet and then fed 0.9% NaCl in drinking water for 3 weeks. Ten days after the start of 
the DOCA-salt regimen, both groups were treated with tamoxifen (100 mg/kg) by oral gavage for 3 consecutive days. Graph represents average mean arte-
rial BP averaged over each 24-hour period. P < 0.05 (slopes test).
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Methods
Cell culture. Human aortic, coronary, and bronchial SMCs were pur-
chased from Lonza and maintained in smooth muscle growth medi-
um-2 (SmGM-2) supplemented with growth factors and 5% FBS. 
Primary aortic SMCs were isolated from 2-month-old Wistar rats as 
previously described (24). In brief, thoracic aortae were stripped of 
endothelial and adventitial layers by microdissection, and then SMCs 
were dispersed by treatment with trypsin and collagenase. Cells were 
maintained in DMEM supplemented with F12 and 10% FBS and used 
from passages 5–15. SMC preparations are routinely tested for smooth 
muscle differentiation marker gene expression, and only those that 
are deemed at least 85% pure by these measurements are used for 
further experimentation. Primary mouse ECs were immortalized by 
transformation with large T antigen (Gibco).
Generation and characterization of ArhGAP42gt/gt SM-MHCCreERT2 
mice. The Arhgap42 gene-trap mouse line was created as previously 
described (11). In brief, Arhgap42 gene-trap embryonic stem (ES) cells 
(SIGTR ES CE0477) were obtained from the Mutant Mouse Regional 
Resource Center (University of California, Davis). Chimeric mice 
were produced in house by blastocyst injection of Arhgap42+/gt ES cells 
using standard procedures, and an Arhgap42gt/gt line on a C57BL/6 
background was generated by backcrossing for at least 8 generations. 
For ARHGAP42 rescue experiments, Arhgap42gt/gt mice were bred to 
a tamoxifen-inducible SM-MHCCreERT2 line provided by Stefan Offer-
manns (University of Heidelberg, Germany) on a pure C57BL/6 back-
ground. Cre activity in this model was controlled by treatment with 
tamoxifen (100 mg/kg) by i.p. injection for 5 consecutive days or 
oral gavage for 3 consecutive days. All experiments were performed 
in male mice 2–4 months old using age- and sex-matched littermate 
genetic controls. Genotyping was performed using DNA isolated from 
tail biopsies using either LacZ (5′-GCATCGAGCTGGGTAATAAGC-
GTTGGCAAT; 3′-GACACCAGACCAACTGGTAATGGTAGCGAC) 
or locus-specific primers (5′-TTCGTTGAGACAACTGCACACC; 
3′-CCCTTCACACTTTGCTCTCTTAGC).
BP measurements. Conscious BP measurements were made in 
mice aged 9–20 weeks by radiotelemetry using the PA-C10 tele-
meter (Data Sciences International) or tail cuff methods using the 
BP-100 probe (Iworx). For telemetry, after positioning of the telem-
etry catheter tip in the thoracic aorta (fed through the left carotid), 
the transmitter was inserted s.c. on the back/flank of mice. Mice were 
housed individually in a standard polypropylene cage placed on a 
radio receiver, maintained in a 12-hour light/dark cycle, and allowed 7 
days of recovery/equilibration before BP measurements were begun. 
All BP measurements were recorded and stored using the Ponemah 
v6.10 system (Data Sciences International). Five-minute record-
ings were collected every 30 minutes, and data were analyzed using 
Excel software. Tail cuff measurements were performed as previ-
ously described (11). In brief, mice were fitted with the BP-100 probe 
and subjected to 20 BP measurements over 20 minutes every day 
(between 1400 and 1600 hours) for 7 consecutive days.
DNase hypersensitivity. Approximately 80 million fresh 
HuAoSMCs were serum-starved for 24 hours and then washed twice 
with cold 1× PBS. Cells were pooled and collected in cold RSB buf-
fer (10 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl2). Nuclei were 
isolated by lysing of cells in RSB buffer plus 0.1% NP-40 and cen-
trifuging at 500 g for 10 minutes at 4°C. Supernatant was removed 
from the pellet. Pelleted nuclei were suspended in cold 1 DNase 
sion and/or BP regulation. During the completion of the current 
studies, Kato et al. demonstrated that a minor allele variation 7.5 
kb upstream from the ARHGAP42 TSS (rs2055450) was associ-
ated with decreased BP in European, East Asian, and South Asian 
populations as well as methylation of a DNA region within the 
ARHGAP42 first intron (6). According to the 1000 Genomes data-
base and additional genotyping of our mixed-European-descent 
and African American patient populations (Supplemental Table 
2), rs2055450 is in relatively high LD with rs604723, significantly 
extending the functional significance of the minor ARHGAP42 
allele in the control of BP in diverse human populations. However, 
like the other SNPs within the ARHGAP42 BP locus, rs2055450 
is not located in a region that exhibits sequence conservation or 
open/active chromatin signatures. Thus, when coupled with our 
extensive data on the role of the DHS2 and rs604723, it is likely 
that rs2055450 and the other variations in this LD block are 
“bystanders” in regard to the regulation of ARHGAP42 expression 
and BP. In support of this conclusion, the rs633185 SNP (the varia-
tion nearest to a potential regulatory element) had no effect on the 
transcriptional activity of the DHS1 fragment or protein binding to 
a 100-bp probe containing this sequence (Supplemental Figure 3).
Interestingly, the GTEx database indicates that minor 
ARHGAP42 allele LD block was significantly associated with 
increased expression of TMEM133, a hypothetical, uncharacter-
ized RNA just downstream of ARHGAP42. However, as shown 
in Supplemental Figure 5, our RNA sequencing and targeted RT-
PCR data indicate that TMEM133 is not transcribed as a separate 
gene, but is actually an extension of the ARHGAP42 3′-UTR. 
These data fully explain why variations that alter ARHGAP42 
expression also affect TMEM133, and, by default, eliminate 
changes in TMEM133 expression as an explanation for the BP 
locus within ARHGAP42.
Our data add to a growing body of evidence that common 
noncoding variants alter cardiovascular risk by altering transcrip-
tion factor binding and gene expression (34, 35), and support pre-
vious studies implicating RhoA signaling in the regulation of BP 
homeostasis in mice (14, 36, 37). Our human genetic data from 
well-characterized untreated patients confirmed that the minor 
ARHGAP42 allele was associated with decreased BP. Although the 
effect size may be relatively small, it has been observed in multiple 
diverse populations (4–6), indicating that ARHGAP42 genotype 
plays an important role. Although our data support the possibility 
that ARHGAP42 genotype contributes to the susceptibility of Afri-
can Americans to the development of hypertension (1), the very 
low MAF in this population has also made it difficult to confirm 
this idea. Given the paucity of genetic mechanisms that explain 
this susceptibility, we are expanding our genotyping and BP analy-
ses in this population. Our results also suggest that ARHGAP42 
genotyping could also prove useful for individualizing antihy-
pertensive therapies. For example, we predict that hypertensive 
patients homozygous for the major allele would respond better 
to antihypertensive agents that target SMC contractility (an end-
point directly controlled by RhoA) and that hypertensive patients 
homozygous for the minor allele may respond better to agents that 
target cardiac or kidney function. Finally, the regulation of ARH-
GAP42 expression and/or activity provides a novel therapeutic 
target for the development of antihypertensive therapies.
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anti-SRF antibody (Santa Cruz Biotechnology; catalog sc-335) or nor-
mal rabbit IgG antibody (Cell Signaling Technology; catalog 2729) as a 
negative control for nonspecific binding.
SRF affinity precipitations. Nuclear extracts from HuAoSMCs were 
prepared using NUPER nuclear extraction kit (Thermo Fisher Scientif-
ic) according to manufacturer protocol. For precipitations, 5′ biotinylat-
ed 20-bp double-stranded oligonucleotides (2.5 μM final concentration) 
were combined with 200 μg of nuclear extract in binding buffer (10 mM 
HEPES, pH 7.4, 8% glycerol, 1 mM MgCl2, 0.05% Triton X-100, 1.3 mM 
DTT, protease and phosphatase inhibitors) at room temperature with 
rotation. After 10 minutes, streptavidin agarose beads (CL-4B, Sigma-
Aldrich, catalog 85881) were added, and reactions were incubated for 
another 30 minutes. After 2 washes (75 mM KCl, 5 mM HEPES, pH 7.4, 
0.5 mM MgCl2, 4% glycerol, 0.05% Tween-20, 1 mM DTT), precipitates 
were eluted in 2× sample buffer and run in a 10% SDS-PAGE for West-
ern blotting with an SRF antibody (Santa Cruz Biotechnology).
SRF knockdown. The following siRNAs were obtained from Invit-
rogen: nontargeted control (NTC) siRNA (to GFP) 5′-GGUGCGCUC-
CUGGACGUAGCC-3′, SRF 5′-UAAUACUCAUGGCAAACAU[dT]
[dT]-3′ (sense) and 5′-AUGUUUGCCAUGAGUAUUA[dT][dT]-3′ 
(antisense). SRF siRNA was obtained as a sense/antisense mixture. 
HuBrSMCs were transfected with 50 nM SRF or NTC siRNA using 
Dharmafect siRNA transfection reagent (Dharmacon). For luciferase 
assays in SRF knockdown cells, siNTC or siSRF-treated HuBrSMCs 
were split 48 hours after knockdown and then seeded into 24-well cul-
ture plates. The following day, NTC and SRF knockdown cells were 
transfected with pGL3-promoterless, -DHS2C, or -DHS2T constructs. 
Luciferase experiments were performed 48 hours after transfec-
tion of pGL3 reporters. For allele-specific transcript measurements, 
HuAoSMCs were harvested 72 hours after knockdown.
Quantitative PCR. RNA was isolated from cells or tissues using 
RNeasy Mini Kit (Qiagen). RNA was treated with DNase (Qiagen) 
to eliminate contaminating genomic DNA. RNA underwent first-
strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-
Rad). Twenty nanograms cDNA was used in quantitative or semi-
quantitative PCR assays. Semiquantitative PCR primers used were: 
mouse Arhgap42 exons 1–4, 5′-CTGCCCACTCTGGAGTTCAGCG, 
3′-GCTGCACCGATCTGTTCTTTTCG; mouse Arhgap42 exons 
10–17, 5′-GAACCGATTTACACGTTACCCG, 3′-GGTTGGAC-
CAAATATGACACCG; GAPDH, 5′-ATGGGTGTGAACCACGAGAA, 
3′-GGCATGGACTGTGGTCATGA. Real-time PCR primers used 
were: ARHGAP42 exons 2–4, 5′-TTGGAGATGCAGAAACTGATGA, 
3′-TTTGAATCAGTCTACGCCTTTCTTC; rat Arhgap42, 5′-TTCTG-
CATCTCCGATACAGTC, 3′-ATCAAAGAGCTGCTGAAGGATG; 
GAPDH, 5′-ATGGGTGTGAACCACGAGAA, 3′-GGCATGGACT-
GTGGTCATGA. Allele-specific PCR primers for rs604723 variation 
were 5′-TGTTGTTCCAAGGGTTCTT-3′ (T) and 5′-TGTTGTTC-
CAAGGGTTCTC-3′ (C).
CRISPR/Cas9–mediated gene editing. Guide RNAs that flanked 
the 100-bp conserved DHS2 region (see below for sequences) were 
designed using sgRNA CRISPR design tool from the Zhang labo-
ratory (38) and cloned into the sgRNA expression cassette of the 
pSpCas9(BB)-2A-Puro (PX459) plasmid (Addgene; catalog 62988). 
HuBrSMCs were transfected with either 15 μg of PX459 plasmid or 7.5 
μg of PX459 plasmid containing each guide RNA. Forty-eight hours 
after transfection, cells were treated with puromycin (2 μg/ml) for 
48 hours and then allowed to recover in normal growth media for an 
incubation buffer (NEB) and mixed. The nuclei suspension was 
treated with 1 U DNase I (Sigma-Aldrich; D5025) for 15 minutes at 
37°C. After 15 minutes, 50 mM EDTA was added to stop the diges-
tion reaction. DNase I–digested DNA was embedded in low-melt 
agarose plugs to minimize additional shearing, and then blunt-end-
ed, extracted, and ligated to biotinylated linkers (Linker 1a: 5′-Bio-
ACAGGTTCAGAGTTCTACAGTCCGAC-3′; Linker 1b: 5′-GTCG-
GACTGTAGAACTCTGAAC-Amm-3′). Biotinylated fragments were 
digested with MmeI and incubated with streptavidin-coated DynaI 
beads (Invitrogen) to purify digested DNA fragments. A second linker 
was ligated to the MmeI-digested DNA-linker-bead complex, and 
purified DNA fragments were PCR-amplified, sequenced by Illu-
mina/Solexa (Linker 2a: 5′-P-TCGTATGCCGTCTTCTGCTTG-3′; 
Linker 2b: 5′-CAAGCAGAAGACGGCATACGANN-3′), and then 
aligned to the human genome using Bowtie.
For targeted, allele-specific DNase hypersensitivity assays, nuclei 
from heterozygous HuAoSMCs were treated with increasing amounts 
of DNase I from 0 to 1 μg. Reactions were subjected to PCR using prim-
ers specific to the major C or minor T alleles, and PCR band intensities 
were expressed relative to untreated samples set to 1.
Generation of luciferase constructs, DNA transfection, and reporter 
assays. Regulatory regions of interest were PCR-amplified from human 
aortic smooth muscle genomic DNA and then cloned into the pGL3 
basic vector (Promega). HuBrSMCs or ECs were seeded in 24-well 
culture plates the day prior to transfections at a density of approxi-
mately 2.5 × 104 cells per well. Cells were transfected with 50 ng DNA 
per well. In coexpression experiments, cells were transfected with 25 
ng of luciferase reporter DNA and 25 ng of FLAG-tagged myocardin 
or empty expression construct per well. In all experiments, cells were 
transfected in triplicate and a promoterless pGL3 basic vector was 
transfected in parallel. After 48 hours of incubation at 37°C, luciferase 
assays were performed using the Steady-Glo Luciferase Kit (Promega) 
following the manufacturer’s instructions. Raw luciferase values were 
normalized to the activity of the promoterless pGL3 vector.
Electrophoretic mobility shift assays. HuAoSMC nuclear lysates 
were prepared using the Nuclear Isolation kit from Thermo Fisher Sci-
entific. Lysates were dialyzed in Dignam Buffer D (20 mM HEPES, pH 
7.9, 20% [vol/vol] glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM PMSF, 
and 0.5 mM DTT). FLAG-tagged SRF was translated in vitro using the 
TnT kit (Promega). Major and minor allele rs633185 and rs604723 
gel shift probes were prepared by PCR amplifying a 100-bp fragment 
from the corresponding DHS1 or DHS2 luciferase reporter plasmids 
with the polymorphism at the center. Each binding reaction contained 
10 μg lysate or 1 μl in vitro–translated SRF, 20,000 cpm of 32P-labeled 
oligonucleotide probe, and 0.20 μg dIdC in binding buffer (10 mmol/l 
Tris, pH 7.5, 50 mmol/l NaCl, 100 mmol/l KCl, 1 mmol/l DDT, 1 
mmol/l EDTA, 5% glycerol).
ChIP experiments. ChIP assays were performed according 
to X-ChIP protocol (Abcam) with slight modifications. In brief, 
HuAoSMCs or human coronary SMCs (HuCoSMCs) were fixed for 
5 minutes in 0.7% formaldehyde. The cross-linking reaction was 
stopped by incubation of cells with 0.125 M glycine for 5 minutes. 
Cells were scraped in lysis buffer (5 mM PIPES, pH 8.0, 85 mM KCl, 
0.5% NP-40) and then nuclei isolated by centrifugation at 2,300 g for 
5 minutes. Nuclei lysis buffer (50 mM Tris-Cl, pH 8.1, 10 mM EDTA, 
0.13% SDS) was added to pelleted nuclei. Chromatin was sheared into 
500-bp fragments by sonication and immunoprecipitated with 1 μg of 
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representative of at least 3 individual experiments, and band inten-
sities were quantified using ImageJ software (NIH).
Study approval. The present studies in animals and/or humans 
were reviewed and approved by an appropriate IRB. All animal pro-
cedures were approved by the IACUC of the University of North 
Carolina at Chapel Hill. All animals were housed in facilities accred-
ited by the Association for Assessment and Accreditation of Labo-
ratory Care International. All clinical investigations were conduct-
ed according to Declaration of Helsinki principles and have been 
approved by the IRB at the University of North Carolina at Chapel 
Hill (IRB: UNC 10-0595). All human study procedures took place in 
a clinical research center, and all subjects provided informed con-
sent prior to their participation in the study.
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additional 24 hours. Genomic DNA and mRNA were isolated using the 
AllPrep DNA/RNA Kit (Qiagen). Deletion efficacy was tested by PCR 
using primers that flanked the deleted region. ARHGAP42 message 
was measured using semiquantitative PCR as described above. Guide 
RNAs used were as follows: gRNA1 sense, 5′-CACCGCTTGGAA-
CAACATTAGACTG; gRNA1 antisense, 5′-AAACCAGTCTAATGTT-
GTTCC AAGC; gRNA2 sense, 5′-CACCGCAGCTGGACTGTGGGT-
CAGA; gRNA2 antisense, 5′-AAACTCTGACCCACAGTCCAGCTGC.
Cell and vessel stretch assays. The Flexercell FX-4000 Tension 
apparatus (Flexcell International Corp.) uses regulated vacuum pres-
sure to deform flexible-bottomed culture plates. Rat aortic SMCs 
were cultured on collagen I–coated BioFlex culture plates and were 
loaded into the FX-4000T cyclic tension device and subjected to 0 
or 20% equibiaxial elongation at 1 Hz for 18 hours. Longitudinally 
cut rat portal vein strips were placed into ex vivo culture in DMEM/
F12 with 2% dialyzed FCS and 10 nM insulin as previously described 
(30, 39). Strips were stretched for 3 days by attachment of a 600-mg 
stainless steel weight at 1 end of the vessel. Mouse portal vein rings 
were cultured as above and subjected to 300 mg of stretching force 
for 5 days. For LacZ staining, tissues were rinsed in PBS and fixed 
in 4% paraformaldehyde for 20 minutes at room temperature. After 
three 10-minute washes in PBS, tissues were incubated overnight at 
room temperature in X-gal staining solution (in PBS; 2 mM MgCl2, 
5  mM ferrocyanide, 5  mM ferricyanide, 0.1% sodium deoxycholate, 
0.2% NP-40, and 1  mg/ml X-gal). Tissues were processed for stan-
dard microscopy including H&E staining.
Hypertension models. For DOCA-salt experiments, mice were 
implanted s.c. with a 50-mg 21-day slow-release DOCA pellet (Inno-
vative Research of America) and fed 0.9% NaCl in drinking water for 
3 weeks. Control mice were subjected to a sham operation and fed 
water. For l-NAME experiments, mice were treated with l-NAME in 
drinking water (450 mg/l) for 14 days. All groups were maintained on 
standard chow.
Human subjects. In brief, participants were enrolled via a com-
bination of passive (signs) and active (e-mail) recruitment. Poten-
tially eligible participants included adults 30 years or older, with 
a recent office (clinic) BP measurement that was borderline high 
(120–149 mmHg systolic and/or 80–95 mmHg diastolic with nei-
ther value greater than 149/95 mmHg). Exclusion criteria included 
diabetes, pregnancy, dementia, any condition that would preclude 
wearing an ambulatory BP monitor, and persistent atrial fibril-
lation or other arrhythmia. Written informed consent took place 
during the first visit, during which time the patients were given 
ample opportunity to ask questions and to review the consent form 
in detail. In addition to carefully measured triplicate office BP 
measurements, participants underwent 24-hour ambulatory BP 
monitoring (ABPM) using the Oscar 2 oscillometric monitor (Sun-
tech Medical). The monitors were programmed to measure BP at 
30-minute intervals from 6 am to 10 pm and at 1-hour intervals 
from 10 pm to 6 am. The minimum number of readings we accept-
ed as an adequate ABPM session was 14 for awake and 6 for sleep. 
ARHGAP42 genotype at rs604723 and rs2055450 was determined 
on patient blood samples as previously described (11).
Statistics. All data represent at least 3 separate experiments 
presented as means ± SEM. Means were compared by 2-tailed Stu-
dent’s t test or ANOVA (where indicated), and statistical signifi-
cance was considered as a P value less than 0.05. All gels shown are 
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